Acorda reports first quarter 2020 financial results and provides business update

Acorda reports first quarter 2020 financial results and provides business update.q1 non-gaap loss per share $0.51.q1 gaap loss per share $0.14.reiterates 2020 ampyra net revenue guidance and operating expense guidance.withdraws 2020 inbrija net revenue guidance due to ongoing covid-19 pandemic.acorda therapeutics - at march 31, had cash, cash equivalents, short-term investments,restricted cash of $126.3 million versus $168.9 million at year end 2019.for full-year 2020, acorda continues to expect ampyra net revenue to be $85 - $110 million.continues to expect inbrija peak sales in 2020 to be $300 million - $500 million.
ACOR Ratings Summary
ACOR Quant Ranking